Prostate News Archive
19-Feb-2007
Preclinical Efficacy Data On Medivation's MDV3100 To Be Presented At ASCO-sponsored Prostate Cancer Symposium (Medical News Today)
Medivation, Inc. (Amex: MDV) today announced that preclinical efficacy data on MDV3100, a novel small molecule the Company is developing to treat hormone-refractory prostate cancer, will be presented later this month at the prostate Cancer Symposium, a gathering sponsored by the American Society of Clinical Oncology. Charles Sawyers, M.D. [click link for full article] Spectrum Pharmaceuticals Announces Completion Of NDA Filing For Satraplatin For Hormone Refractory Prostate Cancer (Medical News Today)
Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI) today announced the completion of the submission of the New Drug Application (NDA) to the US Food & Drug Administration (FDA) for satraplatin, the Company's lead drug candidate for the treatment of hormone refractory prostate cancer (HRPC) for those patients who have failed prior chemotherapy. [click link for full article] Noscapine effective against prostate cancer (News-Medical-Net)
A presentation made at the 17th International prostate Cancer Update Conference in Vail, Colorado, has shown noscapine to be effective against prostate cancer.
Back to Prostate News Archive
